poisar

Stocks · News reference

Helus Pharma Announces Positive Phase 3 Results for HLP003 and Reports Fiscal Q2 2027 Financial Results

Fiscal.ai

Helus Pharma reported positive topline results from its Phase 3 APPROACH study for HLP003 in major depressive disorder and announced key executive leadership changes alongside its fiscal second quarter 2027 financial results.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncHelus Pharma Inc.

    Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026

    Helus Pharma announced it will present topline results from its Phase 3 APPROACH study evaluating HLP003 for major depressive disorder on November 16, 2026. HLP003, a novel serotonergic agonist, has received FDA Breakthrough Therapy Designation. The company is also developing HLP004 for generalized anxiety disorder in Phase 2 trials.